Pharmaceutical research and industrial operations generate vast volumes of sensitive data across drug discovery, formulation development, manufacturing, and distribution, necessitating secure, transparent, and reliable digital infrastructures. The global counterfeit drug market exceeds $200 billion annually, posing a significant threat to patient safety and public health. Blockchain Technology (BT) has demonstrated the potential to reduce counterfeit medicine circulation by approximately 40%, offering a transformative framework for pharmaceutical data governance.

A systematic literature review was performed using ScienceDirect, PubMed, IEEE Xplore, and SpringerLink databases to analyze peer-reviewed studies published between January 2017 and December 2024. Structured keyword strategies and predefined inclusion and exclusion criteria were employed to evaluate blockchain-driven pharmaceutical operations and their integration with Artificial Intelligence (AI) and the Internet of Things (IoT).

The findings reveal that BT substantially improves data integrity, immutability, traceability, transparency, and security across pharmaceutical workflows. Integration with AI and IoT further enables real-time monitoring and predictive analytics, leading to 30-55% improvements in operational efficiency, 25-50% reductions in logistics and compliance-related costs, and significant enhancements in clinical trial data accuracy, pharmacovigilance reporting efficiency, intellectual property protection, and genomic data governance and counterfeit drug prevention.

Blockchain-driven pharmaceutical ecosystems represent a paradigm shift in drug development, manufacturing, and distribution. Despite substantial benefits, challenges related to scalability, interoperability, data governance, and regulatory harmonization remain. Future research should prioritize the development of standardized frameworks, scalable architectures, and regulatory policies to accelerate industrial adoption and clinical translation.